COMP <GO>
VKTX vs ELVN // NET PROFIT MARGIN
Viking Therapeutics Inc. (NASDAQ) VS. Enliven Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: VKTX 2
— ELVN 3
■ METRIC PARITY
LAST: $27.28 (+1.56%) • MKT CAP: $3.38B
net-margins
—
LAST: $44.25 (-1.84%) • MKT CAP: $3.30B
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VKTX VS. ELVN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VKTX | ELVN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -26.20% | -8.80 | ELVN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.25% | -2.13% | -6.12 | ELVN | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.02 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 2/9 | +3.00 | VKTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.5 | 54.2 | -7.70 | ELVN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.38B | $3.30B | $73.0M | VKTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VKTX REV | ELVN REV | VKTX GROSS % | ELVN GROSS % | VKTX FCF | ELVN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$278.7M | -$70.3M |
| FY 2024 | $0 | $0 | — | — | -$87.8M | -$73.2M |
| FY 2023 | $0 | $0 | — | — | -$73.4M | -$61.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VKTX // BETA 0.91
ELVN // BETA —